Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

The Commission has received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the “EUMR”). On 22 January 2019, KKR & Co. Inc. (“KKR”) notified its intention to acquire indirect joint control of Genesis Care Pty Limited (“Genesis Care”), which is currently solely controlled by China Resources (Holdings) Company Limited (“China Resources”) within the meaning of Article 3(1)(b) and Article 3(4) of the EUMR by way of share transfers.

The areas of activities of the undertakings concerned by the notified concentration are as follows:

(i) KKR is incorporated in the United States and is a global investment firm which offers a broad range of alternative asset management services to public and private market investors and provides capital markets solutions for the firm, its portfolio companies and clients;

(ii) China Resources is a diversified holding company registered in Hong Kong which is ultimately supervised by the State-owned Assets Supervision and Administration Commission of the State Council of the People’s Republic of China. It serves as the top level holding company for a group of companies operating a wide variety of businesses, such as consumer products (including retail, beer, food and beverages), power, real estate, cement, gas and pharmaceuticals, as well as various other businesses.

(iii) Genesis Care is a company incorporated in Australia, active in the provision of cancer care (primarily oncology) services in the United Kingdom, Spain and Australia. It also provides radiation therapy treatments for benign diseases in Spain and Australia, and cardiology, sleep and respiratory treatment services in Australia.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.